The New York Daily News reports that The Drug Enforcement Administration and Major League Baseball are investigating a Miami-area man named Anthony Bosch for possible links to performance-enhancing drugs. The significance of Bosch: he has been an adviser on training, nutrition and dietary supplements to Alex Rodriguez and other Latin ballplayers in south Florida.
Bosch is not a new name to people who follow the PED news, as MLB first investigated Bosch and his father, Dr. Pedro Bosch, for their ties to Manny Ramirez back in 2009 when he first tested positive for PEDs when with the Los Angeles Dodgers. Pedro Bosch provided Ramirez the prescription for the female fertility drugs he was taking, and it was reported then that Ramirez had a relationship with Anthony Bosch, as did many other players.
The question I have is what’s new here? We wrote about baseball and the feds’ interest in Pedro and Anthony Bosch here at HardballTalk back in 2009, wondering whether this wasn’t some “Latin American BALCO” situation. Nothing of note has been reported since then, but obviously MLB has had cause to focus more closely on Bosch now to inspire what the Daily News describes as “an ongoing probe.”
The story notes the rise of the use of synthetic testosterone and human growth hormone in Major League Baseball. It’s possible, then, that new information has arisen connecting the Bosch family to the spike in use of these substances. Which, based on positive test results anyway, have disproportionately implicated Latin ballplayers. No one connected to the investigation is commenting, however, so it’s unclear.
One thing that is interesting, though, is the Daily News’ focus on A-Rod here. While there is clearly a connection between Bosch and Rodriguez making reference to him totally legitimate, A-Rod has not tested positive for anything nor has he otherwise been tied to PEDs since his admission to prior use several years ago. Does this suggest that his name may soon be connected to PEDs anew? Or is this just an instance of a New York paper leading with the big name to snag eyeballs?
Definitely worth watching going forward.
The Mets are currently enjoying the spoils of the best young rotation in the game, but the big question is whether this is just a brief window or the start of sustained success. Given the huge prices on the free agent market, it’s going to be next to impossible to keep the band together, but at least one member of the rotation is open to sticking around for the long-term.
While there haven’t been any talks yet, All-Star right-hander Jacob deGrom told Kevin Kernan of the New York Post that he could see himself discussing an extension with the Mets.
“I’m a little bit older, so I might be more willing to do something like that,’’ deGrom told The Post at Mets pre-camp. “You just have to look at what is fair so both sides get a decent deal. It’s something I’d have to look into and make sure I agree with it.’’
It makes sense from deGrom’s perspective. He broke into the majors later than most prospects, so he’ll be 28 this June. Depending on whether he qualifies as a Super Two, he’ll be arbitration-eligible for the first time after either 2016 or 2017. Either way, he’s under team control through 2020, which means that he’s currently on track to hit free agency after his age-32 season. The market might not be kind to him even if he manages to stay healthy, so it could behoove him to get as much guaranteed money as possible right now. The Mets could always decide to play things year-to-year, but perhaps deGrom would be willing to settle for a discount in order to get them to buy out a free agent year or two. It’s a really interesting situation to think about, but odds are the two sides will wait on contract talks until he’s arbitration-eligible for the first time.
DeGrom owns a 2.61 ERA in 52 starts over his first two seasons in the majors. Among starters, only Zack Greinke, Jake Arrieta, and Clayton Kershaw have a lower ERA since the start of 2014.
The Royals and third baseman Mike Moustakas have avoided arbitration by agreeing to a two-year, $14.3 million deal, reports Jon Heyman of MLB Network.
The deal, which was initially discussed last month, buys out Moustakas’ final two years of arbitration. Jeffrey Flanagan of MLB.com reports that it’s believed he’ll make $5.6 million in 2016 and $8.7 million in 2017.
The 27-year-old Moustakas posted an underwhelming .668 OPS over his first four seasons in the majors, but he enjoyed a big postseason in 2014 before breaking out last season by batting .284/.348/.470 with 22 home runs and 82 RBI.
ESPN’s Jerry Crasnick reported this morning that free agent reliever Tommy Hunter required core muscle repair surgery earlier this offseason. Coming off a disappointing 2015, it’s understandable why he’s still on the market, but it sounds like he has at least one significant lead.
Marc Topkin of the Tampa Bay Times hears that the Rays are having “advanced talks” with Hunter as they attempt to add an experienced arm to their bullpen. Nothing is considered close and Hunter is also talking to other clubs. Meanwhile, the Rays have been in touch with veteran reliever Ryan Webb while monitoring the trade market.
Hunter posted a 2.88 ERA as a late-inning arm from 2013-2014, but he compiled a mediocre 4.18 ERA over 58 appearances last season between the Orioles and Cubs. On the bright side, his velocity has held steady and his control is still very good. Despite the down year and core muscle surgery, Topkin writes that Hunter may be holding out for a multi-year deal.
Eric O'Flaherty wasn’t the only reclamation project added by the Pirates today, as the club also announced that they have signed left-hander Cory Luebke to a minor league contract with an invitation to spring training.
Luebke once looked like a solid rotation piece for the Padres, but he hasn’t thrown a pitch in the majors since April 27, 2012. He’s undergone a pair of Tommy John surgeries since. Now 30 years old, he logged seven innings in the minors last season before requiring a procedure to remove loose bodies around a nerve in his forearm. The Padres cut ties with him in November after declining a $7.5 million club option for 2016.
It’s hard to count on much from Luebke at this point, but he told Adam Berry of MLB.com that he feels healthy and hopes to compete for a bullpen job in the spring.